drugset / Trial / NCT07351968

A Phase Ib Study to Evaluate the Efficacy and Safety of HRS-2129 in Patients With Knee Osteoarthritis

NCT07351968

Phase 1 Recruiting 200 enrolled Shandong Suncadia Medicine Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Primary Objective: To explore the effectiveness of different doses of HRS-2129 in the treatment of patients with moderate to severe pain in knee osteoarthritis. Secondary Objectives: To evaluate the safety of different doses of HRS-2129 for the treatment of patients with moderate to severe pain in knee osteoarthritis; To evaluate the population pharmacokinetic profile of HRS-2129 in patients with knee osteoarthritis.

Timeline

Start
2026-03-10
Primary completion
2026-08
Completion
2026-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Celecoxib Other / unclassified
Subject HRS-2129 Unknown

Indications